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CLINICAL STAGING
As there is no satisfactory method of clinical staging of
bronchial cancer acceptable to all and agreed to inter-
nationally, we have introduced our own criteria for clini-
cal staging which are tabulated in Table I:
ment of treatment all these patients had an estimated expecta-
tion of life of more than 3 weeks. All the patients had a total
white cell count of more than 4,500 cells/cu.mm. and a blood
urea of less than 40 mg. / 100 ml. Only one patient (no. 10)
had received prior cancer chemotherapy with cyclophospha-
mide, otherwise none of these patients received a concomitant
drug which might have had an effect on the malignancy.
SPECIAL INVESTIGATIONS
The following special investigations were performed on
patients entering this clinical trial: (a) Full blood count,
(b) urinalysis, (c) serum alkaline phosphatase, (d) serum bili-
rubin, (e) serum albumin-globulin determination, (f) blood
urea and uric acid, and (g) X-ray examination of the chest.
Blood counts were repeated biweekly during periods of
active treatment and X-rays of the chest were taken frequently
during periods of active treatment.
At the commencement of treatment all patients were classi-
fied according to the stage of the disease and according to
their performance status.
A radiographic tumour mass in the chest of
between 2·0 and 5·0 cm. in diameter causing
occlusion of a segmental or lobar bronchus
with or without segmental or lobar atelecta-
sis/ consolidation
o hilar lymph node involvement
(Continued on page 35)
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TABLE I. CLINICAL STAGI 'G OF BRONCHIAL CANCER
DETERMINED RADIOGRAPHICALLY
A radiographic tumour mass in the chest of
less than 2·0 cm. in diameter and situated
either in the hilar region (central) or in the
parenchyma (peripheral)




A total of 21 patients suffering from inoperable bronchial
cancer were treated with combined telecobalt and Natulan
therapy.
These patients presented with either one or other of the
following objective criteria of malignancy: (a) Radiographic
evidence of a measurable tumour mass in the chest and/or
(b) clinical evidence of a measurable tumour mass involving
regional lymph nodes or skin.
In \9 of the 2\ patients the diagnosis was confirmed
histologically: 7 were squamous cell carcinoma, 5 were
undifferentiated, 6 were oat cell, I was an adenocarcinoma
and 2 were histologically unknown. These 2 cases, however,
had the clinical criteria and the support of special investiga-
tions to establish the diagnosis of bronchial carcinoma, but
unfortunately bronchoscopic biopsy was not possible. These
two cases have been included in this assessment of results.
The patients' ages varied from 41 to 81 years with an
average age of 60·2 years. There were 17 males and 4 females
in the series. TO patient who had a serious infection, was
actively bleeding, or who had an associated severe systemic
disease was entered on the clinical trial. At the commence-
The treatment of inoperable bronchial carcinoma remains
unsatisfactory. In 1962 one of us (T.F.)' reported on the
value of telecobaIt therapy alone in the treatment of 77
patients suffering from inoperable bronchial cancer, and
in 1965 Brule, Schulemleger and Griscelli' reported thera-
peutic response in bronchogenic carcinoma treated with
atulan (N-Iso-propyl-alpha-[2-methylhydrazino]-p-tolua-
mide hydrochloride; N.S.C. 77213; Ro 46467 Ibenzmetha-
zine).
We have observed objective improvement following the
use of combined Natulan and telecobalt therapy in the
treatment of malignant mesothelioma'" and of inoperable
malignant melanoma.' It therefore appeared logical to us
to treat inoperable bronchial carcinoma with combined
telecobalt and atulan therapy.
*Senior radiotherapist.
tCancer chemotherapist. In receipt of a grant from the National Cancer
Association of South Africa.
:;Professor and Director. Department of Radiotherapy.
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TABLE Ill. CATEGORIES OF RESPONSE TO TREATME1'.'T
The categories of response, as proposed by Karnofsky,"








A radiographic tumour mass in the chest of
more than 5·0 cm. in diameter causing occlu-
sion of the main bronchus with or without
atelectasis/consolidation, or
Hilar lymph node involvement
Radiographic evidence of a pleural effusion
associated with either Tl, T2 or T3 or rib
erosion as in a Pancoast (superior sulcus)
tumour with
Hilar lymph node involvement, or
Supraclavicular or axillary node metastases,
or







No clinically useful effect on the cou~e of the
disease
Disease progresses. 0 subjective benefit
Disease progresses. Subjective benefit without
favourable objective changes
Favourable objective changes without subjec-
tive benefit
{
Subjective benefit and favourable objective
changes in measurable criteria, but of less than





This ystem of clinical staging is open to CrIticism. We are
well aware of its many defects. The chief difficulty lies in
determining whether the hilar lymph nodes are involved or
not, because this finding is responsible for placing the case
either in stage II or stage Ill. All 21 patients in this series
were classified either as stage III or stage IV. Of the 21
cases, 12 were classified as stage III and 9 as stage IV.
We have found this method of clinical staging simple and
atisfactory.
We have found it profitable to assess the patient's per-
formance status at the beginning of treatment. The patient
is placed into one of 4 categories defined as follows
(Table lI):
TABLE 11. CATEGORIES OF PERFORMANCE STATUS (PS)
A orrnal activity
{ Unable to workB Living at home
l Caring for personal needs
j nable to care for personal needsC Living at home
l Needing help
j Very illD Bed-ridden
l Needing hospitalization
Cmegory 1: ( Clinical benefit with favourable objective
i changes in all measurable criteria of disease
{
Distinct subjective benefit with favourable ob-
jective changes in all measurable criteria for
one month or more
)
Objective regression of all palpable or mea-
surable neoplastic disease for one month or
more in a relatively asymptomatic patient who
is able to carry on his usual activities wilhout
undue difficulty. The observed tumour regres-
sion should be unequivocal and, as a sugges-
l
tion, all lesions should be reduced by at least
500 0 . This category applies as long as the re-
gression persists and ends if any. lesion, old or
new, recurs
I
Complete relief of symptoms. if any, and re-
gression of all manifestations resulting from
active disease for one year or more. The rela-
tion to the frequency of therapy is not relevant
if the disease does not recur between courses
of therapy
NOle: Categories apply as long as improvement from baseline
~~~~ .
Superscriptions above 0, A, Band C represent the time
in months of the duration of the response
The stage of the disease and performance status (PS)
of each patient is shown in Table IV.
TABLE IV. AN ANALYSIS OF 21 PATIENTS TREATED WITH RADIOTHERAPY AND NATULAN
Radiorherapy Chemotherapy
C0-60: 3.000 Curie source
PresenrillR H. V. L. 10'4 mm. Pb. Natulan dosage ill mg. ill
""0. Age Sex synlptoms Surgery Pathology Si!e PS Sta~ e D.X.T. 220 KY. number of days and Response
H. v.i.. j·8 mm. ClI. loweSI while cell
Tumour dose ill rods COUIlI
56 FA Cough, haemoptysis. Br. scopy Squamous R. lower B III Co-60: 19.800 mg. in 216 days. I-A'
dyspnoea. pain. cell lobe (I) 2500r in 15 days- Lowest WBC 4.000 Alive and in
Duration: 3 rnths. 3 fields (9/7/65) remission
(2) 2.000r in 10 days-
3 fields (3/9/65)
(3) I.000T in 5 days-
3 fields (8/11/65)
(4) 994r in 5 days-
3 fields (24/12/65\
2 50 MA Dyspnoea. Lobectomy Squamous L. upper B III C0-6U: I.OOOr in 5 27,050 mg. in 394 days. I_A I3
Duration: 4 mths. cell lobe davs-2 fields Lowest WBC 2.600 Alive and in
(I i/l/65) remission
68 MD Cough. haemoptysis. Br. seopy Squamous L. upper B III C0-60: 1.801 r in 9 1.250 mg. in 5 days. 0--0'
Duration: 3 rnths. cell lobe davs-3 fields Lowest WBC 5,100
( 18/5/65)
4 61 MD Cough. infection. Br. seopy Squamous R. lower B III C0-60: 4.750 mg. in 171 days. I-A'
Duration: 3 rnths. cell lobe (I) 2.000r in 12 days- Lowest WBC 3.100 Died of
3 fields (6/5/65) coronary
(2) 1,000r in 5 days- thrombosis
3 fields (28/6/65)
(3) l.000r in 5 days-
3 fields (16/8/65)
(4) 1,000r in 5 days-
3 fields (18/ I0/65)
81 MD Cough. pain. Br. seopy L'ndiffer. R. lower C IV C0-60: 1.013r in 1.250 mg. in 5 days. O-D
Duration: 4 rnths. lobe days - 3 fields Lowest WBC 2.300
(18/1 0/65)
61 MD Cough, pain. Thorac. Undiffer. R. upper D IV Co-60: 667r in 5 days 1,250 mg. in 5 days. 0--0
Duration: 6 mths. lobe - I field (3/5/65) Lowest WBC 17.000
(Conrillued all page 36)




syrnplOms Surgery Pathology Sire
Radiotherapy
C0-60: 3,000 Curie source
H. v.L. /0'4 mm. Pb.
PS SlOge D.X.T. 220 K. V.
H. V.L. j·8 mm. Clt.
Tumour dose in rads
Chemotherapy
Notu/an dosage in mg. in








Undiffer. R. upper A IV
lobe
Crr-60:
(I)2,OOOr in 12 days-
3 fields (5{7{65)
(2) 1,200r in 5 days-
3 fields (7{9{65)
(3) 1,200r in 5 days-
3 fields (1/11{65)
D.X-T.:
(4) 1,500r in 5 days-
I field (1/l1{65-
supraclavicular)




(6) J.200r in 5 days-
3 fields (3/1 /66)





70 M D Cough, haemoptysis,
infection.
Duration: 6 mths.
Br. seopy Undiffer. R. upper B III
lobe
Cr>--60:
(I) 5,390r in 20 days-
3 fields (22{9{64)
(2) 1,000r in 5 days-
2 fields (9{4{65)





9 73 MA Cough, haemoptysis,
dyspnoea.
Duration: 3 mths.





(2) 1,002r in 5 days-
3 fields (10/12165)
(3) 1,000r in 5 days-
3 fields (31/1{66)





10 4 I M A Cough, haemoptysis,
dyspnoea, pain.
Previously Endox-
an 4,000 mg. in 14










(1) 1,995rin 12 days-
3 fields (30{4{65)
(2) 1,199r in 5 days-
3 fields (4{8{65)
(3) 4,500r in 15 days-
I field (8/11/65)






I-A'1,940 mg. in I 12 days.
Lowest WBC 1,300
Oat cell R. main B III
lobe
Br. scopy11 59 MD Cough, dysphagia.
Duration: 2 mths.
Crr-60:
(I) 1,600r in 6 days-
3 fields (7/12{64)
(2) 1,200r in 5 days-
__---,--_----;o----::-_---,--_:---:---:-__--,, c:-_--:-_--=- --::--:-:-:_--=-_3-=-fields_(1Jj2{65)_---=-=_ -c-:::::-c:-----.-:-::----
12 61 MD Cough, pain, glands. Br. scopy Oat cell R. upper B IV Crr-60: 1,000r in 5 9,500 mg. in 50 days. 0-0
Duration: 3 mths. lobe days - 3 fields (Dec. Lowest WBC 900
1964)
13 51 "MD Infection, paralysis,
brain metas.
Duration: 2 mths.
Biopsy Oat cell R. upper D IV
lobe
Crr-60: 1,502r in 7
davs - 3 fields
(22/12/65)
2,000 mg. in 8 days.
Lowest WBe 5,000









(2) 1,196r in 5 days-
3 fields (18/10/65)
(3) 1,184r in 5 days-
3 fields (13/12{65)





15 73 MD Cough, dyspnoea.
Duration: 5 mths.





(I) 2,698r in 12 days-
3 fields (5{4{65)
(2) 2,402r in 8 days-
3 fields (24{5{65)
3,000 mg. in 56 days.
Lowest WBC 5,800
a-A'
16 73 FA Dyspnoea. pain.
haemoptysis.
Duration; 3 mths.







(2) 998r in 5 days-
3 fields (14/2/66)





17 55 FA Cough. pain, glands.
Duration: 6 mths.





(2) 1,500r in 5 days-
3 fields (31/1{66)















(l) 2,000r in 12 days-
2 fields (l3/12{65)
(2) 1,059r in 5 days-
2 fields (2 I{2{66)





MD ~ Male dead.
19 49 MA Dyspnoea, cough.
Duration: 6 mths.
20 51 MA Haemoptysis, loss of
weight.
Duration: 5 mths.
21 65 M A Cough, pain.
Duration: 12 mths.







Anaplas!. R. lower A IV
Ca. lobe
Squamous R. main B III
cell lobe
Unknown R. upper B HI
lobe
FA = Female alive.
Crr-60:
(I) 2,000r in 12 days-
2 fields (22/11{65)
(2) 1,000r in 5 days-
2 fields (2{2{66)
Crr-60:
(I) 2,OOOr in 12 days-
2 fields (l7{9{65)
(2) 1,000r in 5 days-
2 fields (Nov. 1965)
(3) 1,000r in 5 days-




(2) 999r in 5 days-
3 fields (15/1 1{65)
(3) 999r in 5 days-
3 fields (I 0/1 {66)
F D ~ Female dead.
11,650 mg. in 87 days.
Lowest WBC 5,500
5,000 mg. in I 19 days.
Lowest WBC 4,300
5,000 mg. in 132 days.
Lowest WBC 4,400
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n
The performance status at start of treatment was A
in 2, B in 13, C in 4 and D in 2 patients.
TREATMENT
Treatment was administered as follows: A Siemens 3,000
Curie telecobalt unit was used. Using 3 fields, anterior,
lateral and posterior, a tumour dose of 2,000r in 10
treatments over 2 weeks was administered in the first
course of treatment. Variations on this dosage scheme
may be seen in Table IV. At 8 weekly intervals thereafter
a tumour dose of 1,000 - 1,2oor was administered in 5
days. atulan was given by intravenous injections, 250 mg.
from 5 to 15 minutes before irradiation on each treatment
day in 12 of the 21 patients. In the remaining patients,
oral Natulan was administered.
Details of the radiotherapy and atulan doses for each
individual patient are shown in Tables III and IV.
The total dose of Natulan administered varied from
1,250 mg. in 5 days (patient no. 3) to 29,850 mg. in 312
days (patient no. 10). The minimum treatment adminis-
tered to a patient for trial to be considered adequate was
a tumour dose of 500 rads and a Natulan dose of
1.250 mg.
RESULTS
Therapeutic re ults for each patient are shown in Table
IV. Fifteen of the 21 patients showed objective improve-
ment following this treatment. Of the 21 patients, 12 are
till alive and of these 11 are still in remission.
Of the 12 patients with stage III bronchogenic carci-
noma, 10 showed both objective and subjective improve-
ment of more than one month's duration and one showed
subjective improvement only. Of the 9 patients with stage
IV bronchogenic cancer, 5 showed objective and subjec-
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tive improvement of more than one month's duration. Two
of the 2 patients with performance status A, 11 of the 13
patients with performance status B, and 2 of the 4 patients
with performance status C, responded objectively to treat-
ment, but neither of the 2 with performance status D.
TOXICITY
The lowest white cell count recorded for each patient is
shown in Table IV. Leucopenia below 3,000 cells/cu.mm.
was recorded in 6 patients. Thrombocytopenia of clinical
importance was not observed among the patients.
Although nausea was observed in all patients this was
never severe enough to preclude further treatment. Neuro-
logical effects were not observed among the patients.
CONCLUSIONS
The response to treatment with combined telecobalt and
Natulan therapy is encouraging, but no cure can be
claimed in the treatment of advanced inoperable bronchial
cancer by this means. At most the period of extended life
is made more bearable.
In the group of 21 patients with advanced broncho-
genic cancer, better response was seen in those with stage
III (10 out of 12) than those in stage IV (5 out of 9).
As might be expected, there is a direct relationship be-
tween the patient's performance status at the start cf
treatment and his response to treatment.
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